Why might differences arise between child and adult QALYs? In the UK, NICE’s science policy and research team is reviewing NICE’s recommendations on child utilities and QALYs. In Australia, the Medical Research Future Fund has announced it will fund research for the PBAC on the topic. This blog sets out a conceptual framework addressing five key issues in measuring and valuing children’s health as compared to that of adults.
This OHE Research Paper describes a study in which four stated preference methods for anchoring EQ-5D-Y values were compared: visual analogue scale, discrete choice experiment (with a duration attribute), lag-time time trade-off, and the recently developed ‘location-of-dead’ element of the personal utility function (PUF) approach.
OHE Lunchtime Seminar with Alistair McGuire, 3rd February 2020. The seminar will present some preliminary thoughts on the promises offered by personalised medicine that it will allow efficient identification of different target groups and consequently more effective treatment.
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference to the challenges of HTA in the UK. A failure to consistently consider all ultra-rare disease medicines under the HST process could lead to inequalities in access and health outcomes for patients with ultra-rare conditions.
Adrian Towse presented at the Monash Malaysia Health Economics Forum 2019 on three related topics: health system financing in Malaysia; pharmaceutical price regulation and competition in Malaysia; and the potential for using real world evidence to improve the efficiency of the Malaysian health system.